Mucopolysaccharidosis type II, also known as Hunter syndrome, is a rare inherited disorder that progressively affects many parts of the body, occurring almost exclusively in boys and caused by the body’s inability to properly break down certain complex sugar molecules.
Understanding Mucopolysaccharidosis Type II
Mucopolysaccharidosis type II is a condition that touches nearly every aspect of a child’s development and health. When a baby is born with this disorder, they typically appear completely healthy and show no signs of the condition. However, between the ages of two and four years, changes begin to emerge. Parents might first notice that their child’s facial features are becoming fuller, with rounded cheeks, larger lips, a broader nose, and an enlarged tongue. These changes happen gradually as complex sugar molecules called glycosaminoglycans — long chains of sugars that the body normally breaks down and recycles — begin accumulating inside cells throughout the body.
This buildup occurs because children with mucopolysaccharidosis type II lack a crucial enzyme called iduronate-2-sulfatase, or I2S for short. Without enough of this enzyme, the body cannot properly break down two specific types of glycosaminoglycans: dermatan sulfate and heparan sulfate. These molecules were originally called mucopolysaccharides, which is where the condition gets its complicated name. As these sugar molecules collect inside specialized compartments within cells called lysosomes, they interfere with normal cell function and cause damage to organs and tissues throughout the body.
How Common Is This Condition?
Mucopolysaccharidosis type II is considered a rare disease. Estimates suggest that it occurs in approximately one out of every 100,000 to 170,000 male births worldwide. However, the frequency varies significantly by geographic region and ethnic background. Studies have found that the condition is most common in East Asian countries like Japan, South Korea, and Brazil, where it represents the most frequently diagnosed type of mucopolysaccharidosis. In Japan, for instance, the incidence reaches about one in 84,000 live births, while in South Korea it affects roughly one in 74,000 births.
The condition affects boys almost exclusively because it is caused by changes in a gene located on the X chromosome. Boys have only one X chromosome, which they inherit from their mothers, while girls have two X chromosomes. If a boy inherits an X chromosome carrying the altered gene, he will develop the condition. Girls, on the other hand, have a backup X chromosome that can usually provide the missing enzyme, protecting them from developing symptoms. However, rare cases have been reported in girls, typically when one of their X chromosomes is preferentially turned off in most cells.
What Causes Mucopolysaccharidosis Type II
The root cause of mucopolysaccharidosis type II lies in changes to a specific gene called IDS, located on the long arm of the X chromosome at position Xq28. This gene contains the instructions that cells need to produce the iduronate-2-sulfatase enzyme. The IDS gene spans approximately 44,000 base pairs of DNA and contains nine distinct segments called exons. When working properly, this gene guides the production of a protein consisting of 550 amino acids that performs the critical job of breaking down dermatan sulfate and heparan sulfate.
Scientists have identified more than 600 different genetic variations that can cause mucopolysaccharidosis type II. These include point mutations, where a single letter in the genetic code is changed; frameshift mutations, where insertions or deletions throw off the reading frame of the gene; splice site mutations, which affect how the gene’s segments are joined together; and deletions, where portions of the gene are missing entirely. Some mutations completely eliminate enzyme production, while others reduce it to varying degrees. The specific type of genetic change often influences how severe the condition becomes, with complete gene deletions and nonsense mutations typically causing more severe forms of the disease.
Passing the Condition from Parents to Children
Mucopolysaccharidosis type II follows an X-linked recessive inheritance pattern. This means that the genetic change responsible for the condition is located on the X chromosome. Women who carry one altered copy of the IDS gene typically do not experience symptoms themselves because their second X chromosome provides enough functional enzyme. However, these carrier women have a 50 percent chance with each pregnancy of passing the altered gene to their children. If they have a son who inherits the altered gene, he will develop the condition. If they have a daughter who inherits the altered gene, she will become a carrier like her mother.
Families who have a child with mucopolysaccharidosis type II or who have a family history of the condition can benefit from genetic counseling. Carrier testing is available for female relatives of affected boys to determine whether they carry the altered gene. Additionally, prenatal testing during pregnancy can identify whether a developing baby has inherited the genetic change. This information helps families make informed decisions and prepare for their child’s medical needs.
Risk Factors
The primary risk factor for mucopolysaccharidosis type II is having a biological family member with the disease. If a woman is known to carry the altered IDS gene, any sons she has face a 50 percent chance of inheriting the condition. Brothers of affected boys may also be at risk if their mother is a carrier. Male gender itself is a significant risk factor because boys have only one X chromosome, meaning a single altered copy of the IDS gene is sufficient to cause the disease.
Certain ethnic populations appear to have slightly higher rates of mucopolysaccharidosis type II. The condition is particularly common in East Asian populations, where it represents the most frequently diagnosed form of mucopolysaccharidosis. However, the disease has been reported in individuals of all ethnic backgrounds worldwide. Some specific genetic changes in the IDS gene appear to be more common in certain populations; for example, studies of Chinese patients have identified several mutation sites that occur repeatedly in that population.
Recognizing the Symptoms
Children with mucopolysaccharidosis type II are born appearing healthy and typically develop normally during their first two years of life. The earliest signs usually emerge between ages two and four, when parents might notice changes in their child’s appearance. The facial features gradually become coarser, with fuller lips, larger rounded cheeks, a broad nose with widened nostrils, and an enlarged tongue that may protrude from the mouth. The head often grows larger than normal, a condition called macrocephaly, and the neck appears short in proportion to the body.
As glycosaminoglycans accumulate in the airways, breathing difficulties become increasingly common. The vocal cords enlarge, giving the child’s voice a deep, hoarse quality. The airway narrows, making breathing difficult and causing frequent upper respiratory infections. Many children develop sleep apnea, where they experience brief pauses in breathing during sleep. These breathing problems often require medical intervention to keep the airway open and functioning properly.
The skeleton undergoes numerous changes as the disease progresses. Children with mucopolysaccharidosis type II typically grow at a normal rate until around age five, after which their growth slows considerably, leading to short stature. Multiple skeletal abnormalities develop, collectively referred to as dysostosis multiplex, which includes thickening of certain bones, particularly the ribs. Joints become stiff and limited in their range of motion, a condition called contractures, significantly affecting the child’s mobility and ability to perform everyday tasks.
Internal organs are also affected by the accumulation of glycosaminoglycans. The liver and spleen enlarge substantially, a condition known as hepatosplenomegaly, causing the abdomen to protrude. Many children develop hernias, particularly around the belly button (umbilical hernia) or in the lower abdomen (inguinal hernia). The skin often becomes thick and less elastic, and some children develop distinctive white, pebble-like skin growths.
Hearing and vision problems are common. Most children develop progressive hearing loss caused by a combination of frequent ear infections, fluid buildup in the middle ear, and damage to the inner ear structures. Some individuals experience problems with the retina at the back of the eye, leading to reduced vision. Carpal tunnel syndrome, characterized by numbness, tingling, and weakness in the hands and fingers, frequently develops when accumulated material compresses the nerve running through the wrist.
The heart suffers significant damage in many individuals with mucopolysaccharidosis type II. Heart valves often malfunction, unable to open and close properly. This valve disease causes the heart chambers to enlarge, a condition called ventricular hypertrophy, as the heart works harder to pump blood. Over time, this can lead to abnormal heart rhythms called arrhythmias and eventually heart failure. Heart disease and airway obstruction represent the major causes of death in both severe and milder forms of the condition.
Two Forms of the Disease
Mucopolysaccharidosis type II is traditionally divided into two main forms that differ in severity and which organs are most affected. The neuropathic form, also called the severe form, occurs in approximately 60 percent of individuals with the condition. In this form, the central nervous system becomes significantly involved, with glycosaminoglycans accumulating in the brain and causing progressive damage. Children with the severe form typically develop normally until around ages three or four, when they begin showing behavioral changes, attention difficulties, and speech delays.
As the severe form progresses, children experience cognitive decline and poor performance in school. Between ages six and eight, they begin losing basic functional skills they had previously mastered, a process called developmental regression. Intellectual function continues to deteriorate, and many children develop seizures. The severe form progresses rapidly, and individuals typically have a life expectancy of 10 to 20 years. The combination of neurological decline, heart disease, and airway complications ultimately proves fatal.
The non-neuropathic form, also called the attenuated or milder form, affects the remaining 40 percent of individuals. In this form, the central nervous system remains minimally affected or completely spared. Children maintain normal intelligence and cognitive development throughout their lives. However, this does not mean the disease is without serious effects. The accumulation of glycosaminoglycans in other organ systems can still be severe, causing significant problems with the heart, bones, joints, airways, and other organs.
Individuals with the non-neuropathic form typically live longer than those with the severe form, often surviving into their twenties, thirties, or even sixties. Some may develop mild neurological symptoms at advanced stages of the disease, including retinal degeneration. Despite the preservation of intellectual function, these individuals still face considerable health challenges and shortened lifespans compared to the general population, primarily due to heart disease and respiratory complications.
How the Disease Affects the Body
The underlying problem in mucopolysaccharidosis type II involves the inability of cells to perform normal housekeeping functions. Every cell in the body contains lysosomes, which act as recycling centers that break down and reuse various molecules. The iduronate-2-sulfatase enzyme normally works inside these lysosomes to break down dermatan sulfate and heparan sulfate, two types of glycosaminoglycans that are naturally produced as the body builds and maintains connective tissues throughout the body.
When the iduronate-2-sulfatase enzyme is missing or present at insufficient levels, these glycosaminoglycans cannot be broken down. Instead, they accumulate inside the lysosomes, which become swollen and distended with stored material. This buildup disrupts numerous cellular processes, including cell adhesion (how cells stick together), endocytosis (how cells take in materials from their surroundings), and transport of materials within and between cells. As more and more material accumulates, cells malfunction and eventually die, causing progressive damage to tissues and organs.
The effects of glycosaminoglycan accumulation vary depending on the organ system involved. In bone and cartilage, the buildup interferes with normal skeletal development and growth, leading to the characteristic skeletal abnormalities and short stature. In the airways, accumulated material thickens tissues and narrows passages, causing breathing difficulties. In the heart, glycosaminoglycans collect in heart valves and heart muscle tissue, disrupting normal cardiac function. In the brain, when the severe form of the disease is present, the accumulation damages neurons and other brain cells, leading to progressive neurological decline.
The accumulation of glycosaminoglycans also triggers inflammatory responses in various tissues. This inflammation contributes to tissue damage and scarring, compounding the direct effects of material storage. The combination of cellular dysfunction, mechanical effects from accumulated material, and ongoing inflammation creates a progressive cycle of damage that affects multiple organ systems simultaneously, explaining why mucopolysaccharidosis type II causes such wide-ranging and complex health problems.
Can Mucopolysaccharidosis Type II Be Prevented?
Currently, there is no way to prevent mucopolysaccharidosis type II from developing in a child who has inherited the altered IDS gene. However, families can take steps to identify their risk before or during pregnancy. Women who have a family history of the condition can undergo carrier testing to determine whether they have an altered copy of the IDS gene. This blood test looks for the specific genetic changes known to cause the condition or measures the activity of the iduronate-2-sulfatase enzyme.
For women who know they are carriers, prenatal testing is available during pregnancy to determine whether the developing baby has inherited the altered gene. This testing can be performed using two different procedures. Chorionic villus sampling involves taking a small sample of placental tissue, typically between 10 and 13 weeks of pregnancy. Amniocentesis involves collecting a sample of the fluid surrounding the baby, usually performed between 15 and 20 weeks of pregnancy. Both procedures can identify whether the baby has the genetic change and, if the baby is male, whether he will develop mucopolysaccharidosis type II.
Genetic counseling provides invaluable support for families considering having children when there is a family history of mucopolysaccharidosis type II. Genetic counselors help families understand their risks, explain testing options, and discuss the implications of test results. This information empowers families to make informed decisions that align with their values and circumstances. Some families may choose to pursue reproductive technologies such as in vitro fertilization with genetic testing of embryos, allowing them to select embryos without the altered gene for implantation.
Newborn screening programs in some regions now include testing for mucopolysaccharidosis type II. These programs measure the activity of the iduronate-2-sulfatase enzyme in blood samples collected from newborns shortly after birth. Early detection through newborn screening allows treatment to begin before significant organ damage occurs, potentially improving long-term outcomes. However, newborn screening for this condition is not yet universally available and remains limited to certain states or countries.
